Funds back $270m series-A for BioNTech

The round was led by US hedge fund Redmile Group, with participation from Janus Henderson Investors, Invus, Fidelity Management & Research Company and several European family offices.

Struengmann Family Office committed fresh capital to the round and retained a majority stake in the company; early backer MIG Fonds also retained its stake.

BioNTech will use the fresh capital to further advance its clinical pipeline of individualised immunotherapies.

In September 2017, it signed a collaboration agreement with Genentech, a member of the Roche Group, which involved a one-off $310m payment to BioNTech in exchange for shared marketing rights. This followed similar deals in 2015 with pharmaceutical companies Eli Lilly and Genmab, which paid $60m and $10m to BioNTech respectively.

Previous funding
In November 2008, AT Impf  and MIG Fonds (via MIG Fonds 7) invested an undisclosed amount in the first round of funding for BioNTech.

Company
BioNTech is a privately held biopharmaceutical company that develops individualised immunotherapy treatments for cancer and other diseases. It has secured five large corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. The company is headquartered in Mainz and was founded in 2008; it employs 650 people.

People
BioNTech – Ugur Sahin, Christoph Huber (founders).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture